Program
lurbinectedin
Also written as “Lurbinectedin”, “lurbinectedin (PM01183)” and “Lurbinectedin (PM01183)”.
Its studies are mostly in Small Cell Lung Carcinoma · Breast Neoplasms · Neoplasms · Sarcoma, Ewing · Leiomyosarcoma, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PharmaMar | 202 open or running | phase 3since Apr 10, 2015 | Apr 6, 2009 | Aug 30, 2029phase 3 · NCT06088290 |
| Jazz Pharmaceuticals | 32 open or running | phase 2since Nov 8, 2021 | Nov 8, 2021 | Jan 28, 2028phase 2 · NCT05734066 |
| Luye Pharma Group | 21 open or running | phase 3since Jul 3, 2024 | Nov 5, 2020 | Dec 31, 2027phase 3 · NCT06496048 |
| Gilead Sciences | 11 open or running | phase 3since Jan 24, 2025 | Jan 24, 2025 | Oct 2029phase 3 · NCT06801834 |
| Hoffmann-La Roche | 11 open or running | phase 3since Oct 12, 2021 | Oct 12, 2021 | none ahead |
Also a collaborator on its studies: jazz-pharmaceuticals-ireland-limited.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Apr 6, 2009.
- May 6, 20152 phase 2 studiesPharmaMar · NCT02454972, NCT02451007
- Sep 24, 2015Phase 3 study in Small Cell Lung CarcinomaPharmaMar · NCT02566993 · 613 enrolled · United States, Argentina, Austria and more
- Nov 5, 2015Phase 2 study in GlioblastomaPharmaMar · NCT02611024 · 316 enrolled · United States, France, Germany and more
- Nov 5, 2020Luye Pharma Group's first study: phase 1 study in Advanced Solid TumorNew to Luye Pharma GroupLuye Pharma Group · NCT04638491 · 32 enrolled · China
- Sep 2, 20213 phase 1 studiesPharmaMar · NCT05072106, NCT05063318, NCT05101265
- Oct 12, 2021Hoffmann-La Roche's first study: phase 3 study in Small Cell Lung CarcinomaNew to Hoffmann-La RocheHoffmann-La Roche · NCT05091567 · 660 enrolled · United States, Belgium, Germany and more
- Nov 8, 2021Jazz Pharmaceuticals's first study: phase 2 study in Neoplasm MetastasisNew to Jazz PharmaceuticalsJazz Pharmaceuticals · NCT05126433 · 47 enrolled · United States
- Nov 29, 2021Phase 3 study in Small Cell Lung CarcinomaPharmaMar · NCT05153239 · 705 enrolled · United States, Australia, Austria and more
- Feb 2, 2023Phase 2 study in Sarcoma, EwingJazz Pharmaceuticals · NCT05734066 · 60 planned · United States, Canada
- Sep 28, 2023Phase 3 study in LeiomyosarcomaPharmaMar · NCT06088290 · 469 enrolled · United States, Austria, Belgium and more
- Jul 3, 2024Phase 3 study in Small Cell Lung CarcinomaLuye Pharma Group · NCT06496048 · 180 planned · China
- Jan 24, 2025Gilead Sciences's first study: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)New to Gilead SciencesGilead Sciences · NCT06801834 · 695 planned · United States, Argentina, Australia and more
- Mar 5, 2026Phase 2 study in Small Cell Lung CarcinomaJazz Pharmaceuticals · NCT07459634 · 50 planned · United States
- Nov 6, 2026Primary completion moved from 2028-01-31 to 2029-08-04Date moved laterphase 2 · +18 months · NCT07459634
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaLuye Pharma Group · NCT06496048
- Jan 28, 2028Primary completion: phase 2 study in Sarcoma, EwingJazz Pharmaceuticals · NCT05734066
- Aug 4, 2029Primary completion: phase 2 study in Small Cell Lung CarcinomaJazz Pharmaceuticals · NCT07459634
- Aug 30, 2029Primary completion: phase 3 study in LeiomyosarcomaPharmaMar · NCT06088290
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07459634Small Cell Lung Carcinoma · United States | 2 | Recruiting | Jazz Pharmaceuticals | Aug 4, 2029 | 50 |
| NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more | 3 | Recruiting | Gilead Sciences | Oct 2029 | 695 |
| NCT06496048Small Cell Lung Carcinoma · China | 3 | Recruiting | Luye Pharma Group | Dec 31, 2027 | 180 |
| NCT06088290Leiomyosarcoma · United States, Austria, Belgium and more | 3 | Active, not recruiting | PharmaMar | Aug 30, 2029 | 469 |
| NCT05734066Sarcoma, Ewing · United States, Canada | 2 | Recruiting | Jazz Pharmaceuticals | Jan 28, 2028 | 60 |
| NCT05153239Small Cell Lung Carcinoma · United States, Australia, Austria and more | 3 | Completed | PharmaMar | Apr 10, 2026 | 705 |
| NCT05126433Neoplasm Metastasis · United States | 2 | Terminated | Jazz Pharmaceuticals | Dec 20, 2023 | 47 |
| NCT05091567Small Cell Lung Carcinoma · United States, Belgium, Germany and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jul 29, 2024 | 660 |
| NCT05101265Advanced Solid Tumor · Spain | 1 | Recruiting | PharmaMar | Jun 1, 2025 | 24 |
| NCT05072106Advanced Solid Tumor · Spain | 1 | Completed | PharmaMar | Jan 18, 2022 | 11 |
| NCT05063318Advanced Solid Tumors · Spain | 1 | Completed | PharmaMar | Apr 21, 2022 | 14 |
| NCT04638491Advanced Solid Tumor · China | 1 | Completed | Luye Pharma Group | Nov 4, 2023 | 32 |
| NCT02611024Glioblastoma · United States, France, Germany and more | 2 | Completed | PharmaMar | Jul 1, 2025 | 316 |
| NCT02566993Small Cell Lung Carcinoma · United States, Argentina, Austria and more | 3 | Completed | PharmaMar | Feb 24, 2020 | 613 |
| NCT02451007Solid Tumors · United States, Spain | 2 | Completed | PharmaMar | Aug 19, 2016 | 39 |
| NCT02454972Advanced Solid Tumors · United States, Belgium, France and more | 2 | Completed | PharmaMar | Sep 18, 2020 | 345 |
| NCT02421588Ovarian Neoplasms · United States | 3 | Completed | PharmaMar | Oct 12, 2018 | 442 |
| NCT02210364Breast Neoplasms · Belgium, Spain | 1 | Completed | PharmaMar | Oct 2016 | 81 |
| NCT01980667Neoplasms · Switzerland, United Kingdom | 1 | Completed | PharmaMar | Jan 5, 2017 | 41 |
| NCT01970553Neoplasms · Spain, United Kingdom | 1 | Completed | PharmaMar | Oct 2013 | 47 |
| NCT01970540Neuroendocrine Tumors · Spain, United Kingdom | 1 | Completed | PharmaMar | Aug 9, 2017 | 122 |
| NCT01951157Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | PharmaMar | Nov 2016 | 69 |
| NCT01831089Breast Neoplasms · United States, Spain, Switzerland | 1 | Completed | PharmaMar | Jul 2016 | 69 |
| NCT01525589Breast Neoplasms · United States, Spain | 2 | Completed | PharmaMar | Oct 2018 | 111 |
| NCT01405391Major Advanced Solid Tumors Other Than Colorectal · United States | 1 | Completed | PharmaMar | Jan 2016 | 42 |
| NCT01314599Leukemia · United States | 1 | Completed | PharmaMar | Jul 2015 | 45 |
| NCT00877474ADVANCED SOLID TUMORS · United States, Spain | 1 | Completed | PharmaMar | Jun 2011 | 30 |
How it is read
Names in the registry
- “Lurbinectedin”, 13 entries
- “lurbinectedin (PM01183)”, 6 entries
- “Lurbinectedin (PM01183)”, 3 entries
- “PM01183”, 3 entries
- “Lurbinectedin (regions/countries where approved and available)”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 6 studies
- Breast Neoplasms, 3 studies
- Neoplasms, 2 studies
- Sarcoma, Ewing, 1 study
- Leiomyosarcoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.